As ATUM’s Co-founder and CIO, Dr. Sridhar Govindarajan leads the company's automation, machine learning and protein engineering efforts. He has more than 25 years of scientific computing experience. Prior to his current venture, Govindarajan led the computational research in optimizing directed evolution technologies at Maxygen, Inc., and was a Systems Architect at EraGen Biosciences. Dr. Govindarajan has an undergraduate degree from the Indian Institute of Technology (IIT, Mumbai) and received his PhD in Computational Chemistry/Biophysics from the University of Michigan's Department of Chemistry.
Epitopes are the foundation of efficacy in therapeutic antibody discovery. Antibody discovery is severely limited in the targets and epitopes that can be accessed with traditional practices. Advances in molecular simulation and machine learning can over-come these limitations and enable discovery of on-epitope antibodies for traditionally challenging targets.